/ via embl/
Genomics research company focused on precision health advancements
The biotechnology company Illumina has become the newest member of EMBL’s Corporate Partnership Programme (CPP). It rejoins the programme after a 10-year hiatus.
Headquartered in San Diego, California, Illumina is a global genomics and human health company engaged in precision health advancements. Previously, it was a CPP member from 2010–2015.
“I am delighted to see Illumina’s return to the CPP family. This marks an excellent opportunity to further strengthen a very good relationship between our two organisations,” said Vladimir Benes, head of EMBL’s Genomics Core Facility. “I am confident that the CPP membership will further enhance our joint activities, particularly in the area of training, where both organisations have an established, successful track record.”
CPP members benefit from direct connection with EMBL’s world-leading molecular biology research, services, and technology development, and their support enables EMBL to provide additional training opportunities for the next generation of molecular biologists. Specifically, members support EMBL’s scientific training and conferences programme fellowships, as well as the scientific visitor programme, and participate in discussions of future conference topics and practical courses.
“Being part of the EMBL Corporate Partnership Programme underscores Illumina’s dedication to enabling the power of genomics for all,” said Markus Vossmann, Illumina’s General Manager, Germany. “EMBL’s collaborative ecosystem aligns perfectly with our mission.”
He added, “Through this partnership, Illumina and EMBL will foster scientific exchange, accelerate translational research, and support groundbreaking discoveries that shape the future of biological sciences. Together, we aim to create opportunities for joint initiatives, knowledge sharing, and impactful collaborations that empower researchers worldwide.”
For more information on the EMBL CPP, visit the newly updated CPP website.